Eric Meissner, MD, PhD, discusses the takeaways of the ARTISTRY-2, phase 3 study, which compared bictegravir/emtricitabine/tenofovir alafenamide to bictegravir/lenacapavir in adults with HIV who were virologically suppressed.
Eric Meissner, MD, PhD
Advertisement
Meissner is an associate professor and director of HIV and hepatitis patient care and research, Medical University of South Carolina.
Articles by Eric Meissner, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
FDA Grants Priority Review for Dolutegravir in Newborns With HIV
2
10 Infectious Disease Developments That Defined Q2 2026
3
Merck, ADAP Crisis Task Force Agree to Expand IDVYNSO Access in HIV
4
HIV in 2026: Four Experts on Aging, Testing, Equity, and Prevention's Next Era
5